UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

~~Form~~FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended ~~March~~June 3130, 2024

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 5(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ~~______________________________~~_________________ to ~~______________________________~~ __________________

Commission File Number 33-55254-41

BIOETHICS, LTD.
(Exact name of registrant as specified in charter)
NEVADA, NV	87-0485312
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
1661 Lakeview Circle, Ogden, Utah	84403
(Address of principal executive offices)	(Zip Code)
(801) 399-3632
(Issuer’s telephone number, including area code)

BIOETHICS, LTD.
(Exact name of registrant as specified in charter)

NEVADA (NV)		87-0485312
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

1661 Lakeview Circle, Ogden, Utah		84403
(Address of principal executive offices)		(Zip Code)

(801) 399-3632
(Issuer’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: NONE

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ~~[X]~~ ☒ No ~~[ ]~~☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ~~[X]~~ ☒ No ~~[ ]~~☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [☐ ] Accelerated filer [☐ ] Non-accelerated filer ~~[X]~~☒ Smaller reporting company ☒ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ~~[ ]~~ ☐

Indicate by check mark whether the issuer is a shell company (as defined in rule 12b-2 of the Exchange Act). Yes ☒ No ~~[ ]~~☐

As of ~~May~~August 2019, 2024, the issuer had outstanding 1,135,194 shares of common stock, par value $0.001.

BIOETHICS, LTD.

FORM 10-Q

FOR THE QUARTER ENDED ~~MARCH~~JUNE 3130, 2024

INDEX

PART I Financial Information Item 1. Condensed Financial Statements (Unaudited) 3 Item 2. Management’s Discussion and Analysis of Financial Condition 9 and Results of Operations Item 3. Quantitative and Qualitative Disclosures About Market Risk 10 Item 4. Controls and Procedures 10 PART II Other Information Item 1. Legal Proceedings 11 Item 1A. Risk Factors 11 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 11 Item 3. Defaults Upon Senior Securities 11 Item 4. Mine Safety Disclosures 11 Item 5. Other Information 11 Item 6. Exhibits 12 SIGNATURES 12

PART I Financial Information

Item 1. Condensed Financial Statements (Unaudited)		3

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		12

Item 3. Quantitative and Qualitative Disclosures About Market Risk		13

Item 4. Controls and Procedures		14

PART II Other Information

Item 1. Legal Proceedings		15

Item 1A. Risk Factors		15

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		15

Item 3. Defaults Upon Senior Securities		15

Item 4. Mine Safety Disclosures		15

Item 5. Other Information		15

Item 6. Exhibits		16

SIGNATURES		17

2 Table of Contents

PART I – FINANCIAL INFORMATION

Item 1. Condensed Financial Statements (Unaudited)

BIOETHICS, LTD.

CONTENTS

PAGE

		PAGE
Condensed Unaudited Balance Sheets, As of June 30, 2024 and December 31, 2023		4
Condensed Unaudited Statements of Operations, For the three and six months ended June 30, 2024 and 2023		5
Condensed Unaudited Statements of Stockholders’ Deficit, For the three and six months ended June 30, 2024 and 2023		6
Condensed Unaudited Statements of Cash Flows, For the six months ended June 30, 2024 and 2023		7
Notes to Condensed Unaudited Financial Statements For the six months ended June 30, 2024 and 2023		8

~~Condensed~~3 ~~Unaudited~~Table ~~Balance~~of ~~Sheets,~~ Contents

As of March 31, 2024 and December 31, 20234

BIOETHICS, LTD.
Condensed Balance Sheets
(Unaudited)

	June 30,			December 31,
	2024			2023*

ASSETS

CURRENT ASSETS

Cash and cash equivalents	$	10,168		$	138

Total Current Assets		10,168			138

TOTAL ASSETS	$	10,168		$	138

LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES

Accounts payable	$	150,679		$	122,400
Accounts payable - related party		2,500			14,500
Accrued interest - related parties		108,268			98,406
Accrued interest		108,887			98,363
Convertible notes payable		35,000			35,000
Notes payable		190,000			160,000
Notes payable - related parties		266,684			247,734

Total Current Liabilities		862,018			776,403

TOTAL LIABILITIES		862,018			776,403

STOCKHOLDERS' DEFICIT

Preferred stock, $0.01 par value; 25,000,000 shares authorized, -0- shares issued and outstanding		-			-
Common stock, $0.001 par value; 250,000,000 shares authorized, 1,135,194 shares issued and outstanding		1,135			1,135
Additional paid-in capital		500,479			500,479
Accumulated deficit		(1,353,464	)		(1,277,879	)

Total Stockholders' Deficit		(851,850	)		(776,265	)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	10,168		$	138

*Derived from audited information

The accompanying notes are an integral part of these unaudited condensed financial statements.

~~Condensed~~4 ~~Unaudited~~Table ~~Statements~~ of ~~Operations,~~ Contents

For the three months ended March 31, 2024 and 20235

BIOETHICS, LTD.
Condensed Statements of Operations
(Unaudited)

	For the Three Months Ended						For the Six Months Ended
	June 30,						June 30,
	2024			2023			2024			2023

NET REVENUES	$	-		$	-		$	-		$	-

OPERATING EXPENSES

General and administrative		22,979			14,812			50,200			26,839

Total Operating Expenses		22,979			14,812			50,200			26,839

LOSS FROM OPERATIONS		(22,979	)		(14,812	)		(50,200	)		(26,839	)

OTHER INCOME (EXPENSES)

Interest expense		(12,953	)		(11,998	)		(25,385	)		(23,607	)

Total Other Income (Expenses)		(12,953	)		(11,998	)		(25,385	)		(23,607	)

NET LOSS BEFORE INCOME TAXES		(35,932	)		(26,810	)		(75,585	)		(50,446	)

PROVISION FOR INCOME TAXES		-			-			-			-

NET LOSS	$	(35,932	)	$	(26,810	)	$	(75,585	)	$	(50,446	)

BASIC AND DILUTED LOSS PER SHARE	$	(0.03	)	$	(0.02	)	$	(0.07	)	$	(0.04	)

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING		1,135,194			1,135,194			1,135,194			1,135,194

The accompanying notes are an integral part of these unaudited condensed financial statements.

~~Condensed~~5 ~~Unaudited~~Table ~~Statements~~ of ~~Stockholders’ Deficit,~~ Contents

For the three months ended March 31, 2024 and 2023 6

BIOETHICS, LTD.
Condensed Statements of Stockholders' Deficit
(Unaudited)

	Six Months Ended June 30, 2024
					Additional					Total
	Common Stock				Paid-In		Accumulated			Stockholders'
	Shares		Amount		Capital		Deficit			Deficit

Balance, December 31, 2023		1,135,914	$	1,135	$	500,479	$	(1,277,879	)	$	(776,265	)

Net loss for the three months ended March 31, 2024		-		-		-		(39,653	)		(39,653	)

Balance, March 31, 2024		1,135,914		1,135		500,479		(1,317,532	)		(815,918	)

Net loss for the three months ended June 30, 2024		-		-		-		(35,932	)		(35,932	)

Balance, June 30, 2024		1,135,914	$	1,135	$	500,479	$	(1,353,464	)	$	(851,850	)

	Six Months Ended June 30, 2023
					Additional					Total
	Common Stock				Paid-In		Accumulated			Stockholders'
	Shares		Amount		Capital		Deficit			Deficit

Balance, December 31, 2022		1,135,914	$	1,135	$	500,479	$	(1,180,730	)	$	(679,116	)

Net loss for the three months ended March 31, 2023		-		-		-		(23,636	)		(23,636	)

Balance, March 31, 2023		1,135,914		1,135		500,479		(1,204,366	)		(702,752	)

Net loss for the three months ended June 30, 2023		-		-		-		(26,810	)		(26,810	)

Balance, June 30, 2023		1,135,914	$	1,135	$	500,479	$	(1,231,176	)	$	(729,562	)

The accompanying notes are an integral part of these unaudited condensed financial statements.

~~Condensed~~6 ~~Unaudited~~Table ~~Statements~~ of ~~Cash Flows,~~ Contents

For the three months ended March 31, 2024 and 2023 7

BIOETHICS, LTD.
Condensed Statements of Cash Flows
(Unaudited)

	For the Six Months Ended
	June 30,
	2024			2023

CASH FLOWS FROM OPERATING ACTIVITIES

Net loss	$	(75,585	)	$	(50,446	)
Adjustments to reconcile net loss to net cash used by operating activities:
Changes in operating assets and liabilities:
Accounts payable		28,279			11,417
Accounts payable - related party		(12,000	)		3,000
Accrued interest - related parties		9,862			13,293
Accrued interest		10,524			10,314

Net Cash Used by Operating Activities		(38,920	)		(12,422	)

CASH FLOWS FROM INVESTING ACTIVITIES		-			-

CASH FLOWS FROM FINANCING ACTIVITIES

Proceeds from notes payable		30,000			-
Proceeds from notes payable - related parties		18,950			12,600

Net Cash Provided by Financing Activities		48,950			12,600

INCREASE IN CASH AND CASH EQUIVALENTS		10,030			178

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD		138			295

CASH AND CASH EQUIVALENTS AT END OF PERIOD	$	10,168		$	473

SUPPLEMENTAL DISCLOSURES:
Cash paid for interest	$	5,000		$	-
Cash paid for income taxes	$	-		$	-

The accompanying notes are an integral part of these unaudited condensed financial statements.

~~Notes~~7 toTable ~~Condensed~~of ~~Unaudited Financial Statements,~~Contents

~~For the three months ended March 31~~BIOETHICS, ~~2024 and 20238~~ LTD.

3NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

BIOETHICS, LTD.
Condensed Balance Sheets
(Unaudited)
			March 31,	December 31,
			2024	2023*
ASSETS
CURRENT ASSETS
	Cash and cash equivalents		$ 93	$ 138
		Total Current Assets	93	138
		TOTAL ASSETS	$ 93	$ 138
LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES
	Accounts payable		$ 142,225	$ 122,400
	Accounts payable - related party		16,000	14,500
	Accrued interest - related parties		105,667	98,406
	Accrued interest		103,535	98,363
	Convertible notes payable		35,000	35,000
	Notes payable		160,000	160,000
	Notes payable - related parties		253,584	247,734
		Total Current Liabilities	816,011	776,403
		TOTAL LIABILITIES	816,011	776,403
STOCKHOLDERS' DEFICIT
	Preferred stock, $0.01 par value; 25,000,000 shares authorized, -0- shares issued and outstanding		-	-
	Common stock, $0.001 par value; 250,000,000 shares authorized, 1,135,194 shares issued and outstanding		1,135	1,135
	Additional paid-in capital		500,479	500,479
	Accumulated deficit		(1,317,532)	(1,277,879)
		Total Stockholders' Deficit	(815,918)	(776,265)
		TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 93	$ 138
		*Derived from audited information
The accompanying notes are an integral part of these unaudited condensed financial statements.

SIX MONTHS ENDED JUNE 30, 2024 and 2023

4NOTE 1 ‑ SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BIOETHICS, LTD.
Condensed Statements of Operations
(Unaudited)
			For the Three Months Ended
			March 31,
			2024	2023
NET REVENUES			$ -	$ -
OPERATING EXPENSES
	General and administrative		27,221	12,027
		Total Operating Expenses	27,221	12,027
LOSS FROM OPERATIONS			(27,221)	(12,027)
OTHER INCOME (EXPENSES)
	Interest expense		(12,432)	(11,609)
		Total Other Income (Expenses)	(12,432)	(11,609)
NET LOSS BEFORE INCOME TAXES			(39,653)	(23,636)
PROVISION FOR INCOME TAXES			-	-
NET LOSS			$ (39,653)	$ (23,636)
BASIC AND DILUTED LOSS PER SHARE			$ (0.03)	$ (0.02)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING			1,135,194	1,135,194
The accompanying notes are an integral part of these unaudited condensed financial statements.

Organization - Bioethics, Ltd. (“the Company”) was organized under the laws of the State of Nevada on July 26, 1990. The Company was organized to provide a vehicle for participating in potentially profitable business ventures which may become available through the personal contacts of and at the complete discretion of the Company’s officers and directors. The Company has not paid any dividends and any dividends that may be paid in the future will depend upon the financial requirements of the Company and other relevant factors.

5The accompanying financial statements are condensed and have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows for the six months ended June 30, 2024 and 2023 have been made.

BIOETHICS, LTD.
Condensed Statements of Stockholders' Deficit
(Unaudited)
	Three Months Ended March 31, 2024
			Additional		Total
	Common Stock		Paid-In	Accumulated	Stockholders'
	Shares	Amount	Capital	Deficit	Deficit
Balance, December 31, 2023	1,135,914	$ 1,135	$ 500,479	$ (1,277,879)	$ (776,265)
Net loss for the three months ended
March 31, 2024	-	-	-	(39,653)	(39,653)
Balance, March 31, 2024	1,135,914	1,135	500,479	(1,317,532)	(815,918)
	Three Months Ended March 31, 2023
			Additional		Total
	Common Stock		Paid-In	Accumulated	Stockholders'
	Shares	Amount	Capital	Deficit	Deficit
Balance, December 31, 2022	1,135,914	$ 1,135	$ 500,479	$ (1,180,730)	$ (679,116)
Net loss for the three months ended
March 31, 2023	-	-	-	(23,636)	(23,636)
Balance, March 31, 2023	1,135,914	1,135	500,479	(1,204,366)	(702,752)
The accompanying notes are an integral part of these unaudited condensed financial statements.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2023 audited financial statements. The results of operations for the six months ended June 30, 2024 are not necessarily indicative of the operating results for the full year.

6NOTE 2 ‑ RELATED PARTY TRANSACTIONS

BIOETHICS, LTD.
Condensed Statements of Cash Flows
(Unaudited)
			For the Three Months Ended
			March 31,
			2024	2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss			$ (39,653)	$ (23,636)
Adjustments to reconcile net loss to net cash
used by operating activities:
Changes in operating assets and liabilities:
		Accounts payable	19,825	7,482
		Accounts payable - related party	1,500	1,500
		Accrued interest - related parties	7,261	6,481
		Accrued interest	5,172	5,128
		Net Cash Used by Operating Activities	(5,895)	(3,045)
CASH FLOWS FROM INVESTING ACTIVITIES			-	-
CASH FLOWS FROM FINANCING ACTIVITIES
		Proceeds from notes payable - related parties	5,850	3,000
		Net Cash Provided by Financing Activities	5,850	3,000
DECREASE IN CASH AND CASH EQUIVALENTS			(45)	(45)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD			138	295
CASH AND CASH EQUIVALENTS AT END OF PERIOD			$ 93	$ 250
SUPPLEMENTAL DISCLOSURES:
	Cash paid for interest		$ -	$ -
	Cash paid for income taxes		$ -	$ -
The accompanying notes are an integral part of these unaudited condensed financial statements.

Management Compensation - During the six months ended June 30, 2024 and 2023, the Company did not pay any compensation to its officers and directors.

7Beginning August 2017, the Company entered into an oral agreement to pay the Company’s President $500 per month as payment for use of his personal residence as the Company’s office and mailing address. The Company has recorded rent expense of $3,000 during each of the six months ended June 30, 2024 and 2023, which is included in the general and administrative expenses on the statements of operations. The amount payable at December 31, 2023 was $14,500. During the six months ended June 30, 2024, the Company paid 15,000, resulting in $2,500 payable at June 30, 2024.

~~BIOETHICS~~On March 8, ~~LTD~~2018, the Company entered into a promissory note with a newly-affiliated party in the amount of $43,250. The note is payable on demand and carries interest at 10% per annum. Interest expense for the six months ended June 30, 2024 and 2023 was $2,151 and $2,145, respectively, resulting in accrued interest of $27,307 and $25,156 at June 30, 2024 and December 31, 2023, respectively. Principal balance on the note at June 30, 2024 and December 31, 2023 was $43,250.

~~NOTES~~On TODecember ~~UNAUDITED~~12, ~~CONDENSED~~2017, ~~FINANCIAL~~the ~~STATEMENTS~~Company entered into a promissory note with its President in the amount of $107,000. On various dates from the origin of the note through December 31, 2023, the officer advanced the Company an additional $118,170, and the Company made payments of $20,686, resulting in the total note principal balance of $204,484 at December 31, 2023. During the six months ended June 30, 2024 and 2023, the Company received an additional $18,950 and $12,600, respectively, and did not make any repayments of the principal balance resulting in the total note principal balance of $223,434 at June 30, 2024. The cumulative note balance is uncollateralized, due on demand, and carries interest at 12% per annum. Interest expense on the note for the six months ended June 30, 2024 and 2023 was $12,711 and $11,148, respectively, of which the Company repaid $5,000 during the six months ended June 30, 2024, resulting in accrued interest totaling $80,961 and $73,250 at June 30, 2024 and December 31, 2023, respectively.

~~THREE~~NOTE ~~MONTHS~~3 ~~ENDED~~- ~~MARCH~~NOTES ~~31,~~PAYABLE ~~2024 and 2023~~

~~NOTE~~On June 14, 2016, the Company issued a promissory note in the principal amount of $35,000 to an unaffiliated lender. The Note is due on demand at any time after its original maturity date of June 14, 2017, and carries an interest rate of 8% per annum. Interest expense for the six months ended June 30, 2024 and 2023 totaled $1,392 -and ~~SUMMARY~~$1,388, OFrespectively, ~~SIGNIFICANT~~resulting ~~ACCOUNTING~~in ~~POLICIES~~accrued interest at June 30, 2024 and December 31, 2023 of $22,534 and $21,142, respectively. Principal balance due on the note at June 30, 2024 and December 31, 2023 was $35,000.

~~Organization~~8 -Table ~~Bioethics, Ltd. (“the Company”) was organized under the laws~~ of the State of Nevada on July 26, 1990. The Company was organized to provide a vehicle for participating in potentially profitable business ventures which may become available through the personal contacts of and at the complete discretion of the Company’s officers and directors. The Company has not paid any dividends and any dividends that may be paid in the future will depend upon the financial requirements of the Company and other relevant factors.Contents

~~The accompanying financial statements are condensed and have been prepared by the Company without audit. In the opinion of management~~BIOETHICS, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows for the three months ended March 31, 2024 and 2023 have been madeLTD.

~~Certain~~NOTES ~~information~~TO ~~and~~UNAUDITED ~~footnote~~CONDENSED ~~disclosures~~FINANCIAL normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2023 audited financial statements. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the operating results for the full year.STATEMENTS

~~NOTE~~SIX 2MONTHS -ENDED ~~RELATED~~JUNE ~~PARTY~~30, ~~TRANSACTIONS~~2024 and 2023

~~Management~~On ~~Compensation~~August -15, ~~During~~2018, the ~~three~~Company issued a promissory note in the principal amount of $10,000 to an unaffiliated lender. The Note was due on November 15, 2018, is currently in default, and carries an interest rate of 12% per annum. Interest expense for the six months ended ~~March~~June 3130, 2024 and 2023 totaled $597 and $595, ~~the~~respectively, ~~Company~~resulting ~~did~~in ~~not~~accrued ~~pay~~interest ~~any~~at ~~compensation~~June to30, ~~its~~2024 ~~officers~~and December 31, 2023 of $6,304 and ~~directors~~$5,707, respectively. Principal balance on the note at June 30, 2024 and December 31, 2023 was $10,000.

~~Beginning~~On ~~August~~November ~~2017~~15, 2018, the Company ~~entered~~issued ~~into~~a anpromissory ~~oral~~note ~~agreement~~in ~~to pay~~ the ~~Company’s~~principal ~~President~~amount of $~~500~~20,000 ~~per~~to ~~month~~an asunaffiliated ~~payment~~lender. ~~for~~The ~~use~~Note ofwas ~~his~~due ~~personal~~on ~~residence~~February as15, ~~the~~2019, ~~Company’s~~is ~~office~~currently ~~and~~in ~~mailing~~default, ~~address. The~~and ~~Company~~carries ~~has~~an ~~recorded~~interest ~~rent~~rate ~~expense~~ of ~~$1,500~~12% ~~during~~per ~~each~~annum. ofInterest expense for the ~~three~~six months ended ~~March~~June 3130, 2024 and 2023 totaled $1,193 ~~which~~and is$1,190, ~~included~~respectively, resulting in ~~the~~accrued ~~general~~interest ~~and~~at ~~administrative~~June ~~expenses~~30, on2024 ~~the~~and ~~statements~~December ~~of operations~~31, 2023 of ~~which~~ $1612,~~000~~608 and $1411,~~500~~415, ~~remains~~respectively. ~~payable~~Principal balance on the note at ~~March~~June 3130, 2024 and December 31, 2023, ~~respectively~~was $20,000.

On ~~March~~December 831, 2018, the Company ~~entered~~issued ~~into~~ a promissory note ~~with a newly-affiliated party~~ in the principal amount of $4330,~~250~~000 to an unaffiliated lender. The ~~note~~Note iswas ~~payable~~due on ~~demand~~December 31, 2019, is currently in default, and carries an interest atrate 10of 12% per annum. Interest expense for the ~~three~~six months ended ~~March~~June 3130, 2024 and 2023 ~~was~~totaled $1,~~075~~790 and $1,~~066~~785, respectively, resulting in accrued interest ~~of $26,231 and $25,156~~ at ~~March~~June 3130, 2024 and December 31, 2023 of $18,912 and $17,122, respectively. Principal balance on the note at ~~March~~June 3130, 2024 and December 31, 2023 was $4330,~~250~~000.

On ~~December~~January 1223, ~~2017~~2019, the Company ~~entered~~issued ~~into~~ a promissory note ~~with its President~~ in the principal amount of $~~107~~50,000~~. On~~ ~~various~~to ~~dates~~an ~~from~~unaffiliated ~~the~~lender. ~~origin~~The ofNote ~~the~~was ~~note~~due ~~through~~on ~~December~~January 3123, ~~2023~~2022, ~~the~~is ~~officer~~currently ~~advanced~~in ~~the Company an additional $118~~default,~~170,~~ and ~~the~~carries ~~Company~~an ~~made~~interest ~~payments~~rate of ~~$20,686,~~12% ~~resulting~~per inannum. ~~the~~Interest ~~total~~expense ~~note~~for ~~principal balance of $204,484 at December 31, 2023. During~~ the ~~three~~six months ended ~~March~~June 3130, 2024 and 2023, ~~the~~totaled ~~Company received an additional~~ $52,~~850~~984 and $32,~~000~~975, respectively, ~~and did not make any repayments of the principal balance~~ resulting in ~~the~~accrued ~~total~~interest ~~note principal balance of $210,334~~ at ~~March~~June 3130, ~~2024. The~~2024and ~~cumulative~~December ~~note balance is uncollateralized, due on demand, and carries interest at 12% per annum. Interest expense on the note for the three months ended March~~ 31, ~~2024 and~~ 2023 ~~was~~of $631,~~186~~521 and $528,~~414~~537, respectively,. ofPrincipal ~~which~~balance ~~the~~on ~~Company repaid $-0- during~~ the ~~three~~note ~~months ended March 31, 2024, resulting in accrued interest totaling $79,436 and $73,250~~ at ~~March~~June 3130, 2024 and December 31, 2023, ~~respectively~~was $50,000.

~~NOTE~~On 3May -1, ~~NOTES~~2020, ~~PAYABLE~~the Company issued a promissory note in the principal amount of $5,000 to an unaffiliated lender. The Note was due on May 1, 2022 and is now due on demand and carries an interest rate of 12% per annum. Interest expense for the six months ended June 30, 2024 and 2023 totaled $298 and $298, respectively, resulting in accrued interest at June 30, 2024 and December 31, 2023 of $2,490 and $2,191, respectively. Principal balance on the note at June 30, 2024 and December 31, 2023 was $5,000.

On ~~June~~April 1418, ~~2016~~2022, the Company issued a promissory note in the principal amount of $3510,000 to an unaffiliated lender. The Note iswas due on ~~demand~~April at18, ~~any~~2023 ~~time~~and ~~after~~is ~~its~~now ~~original~~due ~~maturity~~on ~~date~~demand ~~of June 14, 2017,~~ and carries an interest rate of 8% per annum. Interest expense for the ~~three~~six months ended ~~March~~June 3130, 2024 and 2023 totaled $~~696~~398 and $~~690~~397, respectively, resulting in accrued interest at ~~March~~June 3130, 2024 and December 31, 2023 of $211,~~838~~761 and $211,~~142~~363, respectively. Principal balance ~~due~~ on the note at ~~March~~June 3130, 2024 and December 31, 2023 was $3510,000.

8On May 9, 2024, the Company issued a promissory note in the principal amount of $10,000 to an unaffiliated lender. The Note is due on May 9, 2025 and carries an interest rate of 10% per annum. Interest expense for the six months ended June 30, 2024 and 2023 totaled $142 and $-0-, respectively, resulting in accrued interest at June 30, 2024 and December 31, 2023 of $142 and $-0-, respectively. Principal balance on the note at June 30, 2024 and December 31, 2023 was $10,000.

~~BIOETHICS~~On June 21, ~~LTD~~2024, the Company issued a promissory note in the principal amount of $10,000 to an unaffiliated lender. The Note is due on June 21, 2025 and carries an interest rate of 10% per annum. Interest expense for the six months ended June 30, 2024 and 2023 totaled $25 and $-0-, respectively, resulting in accrued interest at June 30, 2024 and December 31, 2023 of $25 and $-0-, respectively. Principal balance on the note at June 30, 2024 and December 31, 2023 was $10,000.

~~NOTES~~On TOJune ~~UNAUDITED~~25, ~~CONDENSED~~2024, ~~FINANCIAL~~the ~~STATEMENTS~~Company issued a promissory note in the principal amount of $10,000 to an unaffiliated lender. The Note is due on June 25, 2025 and carries an interest rate of 10% per annum. Interest expense for the six months ended June 30, 2024 and 2023 totaled $14 and $-0-, respectively, resulting in accrued interest at June 30, 2024 and December 31, 2023 of $14 and $-0-, respectively. Principal balance on the note at June 30, 2024 and December 31, 2023 was $10,000.

~~THREE~~9 ~~MONTHS~~Table ~~ENDED~~of ~~MARCH 31, 2024 and 2023~~Contents

~~On August 15~~BIOETHICS, ~~2018, the Company issued a promissory note in the principal amount of $10,000 to an unaffiliated lender~~LTD. The Note was due on November 15, 2018, is currently in default, and carries an interest rate of 12% per annum. Interest expense for the three months ended March 31, 2024 and 2023 totaled $298 and $296, respectively, resulting in accrued interest at March 31, 2024 and December 31, 2023 of $6,006 and $5,707, respectively. Principal balance on the note at March 31, 2024 and December 31, 2023 was $10,000.

OnNOTES ~~November~~TO ~~15,~~UNAUDITED ~~2018,~~CONDENSED ~~the~~FINANCIAL Company issued a promissory note in the principal amount of $20,000 to an unaffiliated lender. The Note was due on February 15, 2019, is currently in default, and carries an interest rate of 12% per annum. Interest expense for the three months ended March 31, 2024 and 2023 totaled $597 and $592, respectively, resulting in accrued interest at March 31, 2024 and December 31, 2023 of $12,012 and $11,415, respectively. Principal balance on the note at March 31, 2024 and December 31, 2023 was $20,000. STATEMENTS

OnSIX ~~December~~MONTHS ~~31,~~ENDED ~~2018,~~JUNE ~~the Company issued a promissory note in the principal amount of $~~30,~~000~~ ~~to an unaffiliated lender. The Note was due on December 31, 2019, is currently in default, and carries an interest rate of 12% per annum. Interest expense for the three months ended March 31,~~ 2024 and 2023 totaled $895 and $888, respectively, resulting in accrued interest at March 31, 2024 and December 31, 2023 of $18,017 and $17,122, respectively. Principal balance on the note at March 31, 2024 and December 31, 2023 was $30,000.

OnNOTE ~~January~~4 ~~23,~~– ~~2019,~~CONVERTIBLE ~~the~~NOTES ~~Company~~PAYABLE issued a promissory note in the principal amount of $50,000 to an unaffiliated lender. The Note was due on January 23, 2020, is currently in default, and carries an interest rate of 12% per annum. Interest expense for the three months ended March 31, 2024 and 2023 totaled $1,492 and $1,479, respectively, resulting in accrued interest at March 31, 2024 and December 31, 2023 of $30,029 and $28,537, respectively. Principal balance on the note at March 31, 2024 and December 31, 2023 was $50,000.

On ~~May~~December 118, ~~2020~~2019, the Company issued a convertible promissory note in the original principal amount of $510,000 to ana ~~unaffiliated~~ lender. The Note was due on ~~May~~June 118, ~~2021~~2020, ~~and~~ is ~~now~~currently ~~due~~in ondefault, ~~demand~~ and carries an interest rate of 128% per annum. The Note is due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $2.00 per share. The Company recognized a beneficial conversion feature and recorded a debt discount in the amount of $4,000, which was amortized over the life of the promissory note. At June 30, 2024 and December 31, 2023, the unamortized debt discount was $-0-, and the net convertible note balance was $10,000. The amortization of debt discount was $- 0- during the six months ended June 30, 2024 and June 30, 2023. Interest expense for the ~~three~~six months ended ~~March~~June 3130, 2024 and ~~2023~~2023totaled ~~totaled~~ $~~149~~597 and $~~148~~595, respectively, resulting in accrued interest at ~~March~~June 3130, 2024 and December 31, 2023 of $23,~~340~~827 and $23,~~191~~231, respectively. Principal balance on the note at ~~March~~June 3130, ~~2024~~2024and ~~and~~ December 31, 2023 was $510,000.

On ~~April~~June 189, ~~2022~~2020, the Company issued a convertible promissory note in the original principal amount of $10,000 to ana ~~unaffiliated~~ lender. The Note iswas due on ~~April~~June 189, ~~2023~~2021, is currently in default, and carries an interest rate of 810% per annum. The Note is due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $2.50 per share. The Company recognized a beneficial conversion feature and recorded a debt discount in the amount of $6,200, which was amortized over the life of the promissory note. At June 30, 2024 and December 31, 2023, the unamortized debt discount was $- 0, and the net convertible note balance was $10,000. The amortization of debt discount was $- 0- during the six months ended June 30, 2024 and 2023, respectively. Interest expense for the ~~three~~six months ended ~~March~~June 3130, 2024 and 2023 totaled $~~199~~497 and $~~197~~496, respectively, resulting in accrued interest at ~~March~~June 3130, 2024 and December 31, 2023 of $14,~~532~~059 and $13,~~363, respectively~~562. Principal balance on the note at ~~March~~June 3130, 2024 and December 31, 2023 was $10,000.

~~NOTE~~On August 3, 2020, the Company issued a convertible promissory note in the original principal amount of $15,000 to a lender. The Note was due on August 3, 2021, is currently in default, and carries an interest rate of 8% per annum. The Note is due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $7.00 per share. The Company did not recognize a beneficial conversion feature or debt discount as the conversion price was higher than the market price at the time of issuance of the note. Interest expense for the six months ended June 30, 2024 and 2023 totaled $597 and $595, respectively, resulting in accrued interest at June 30, 2024 and December 31, 2023 of $4,690 ~~– CONVERTIBLE~~and ~~NOTES~~$4,093. ~~PAYABLE~~Principal balance on the note at June 30, 2024 and December 31, 2023 was $15,000.

OnNOTE ~~December~~5 ~~18,~~– ~~2019,~~EQUITY the Company issued a convertible promissory note in the original principal amount of $10,000 to a lender. The Note was due on June 18, 2020, is currently in default, and carries an interest rate of 8% per annum. The Note is due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $2.00 per share. The Company recognized a beneficial conversion feature and recorded a debt discount in the amount of $4,000, which was amortized over the life of the promissory note. At March 31, 2024 and December 31, 2023, the unamortized debt discount was $-0-, and the net convertible note balance was $10,000. The amortization of debt discount was $-0- during the three months ended March 31, 2024 and March 31, 2023. Interest expense for the three months ended March 31, 2024 and 2023 totaled $298 and $296, respectively, resulting in accrued interest at March 31, 2024 and December 31, 2023 of $3,529 and $3,231, respectively. Principal balance on the note at March 31, 2024 and December 31, 2023 was $10,000.TRANSACTIONS

OnThe ~~June 9, 2020, the~~ Company ~~issued~~is aauthorized ~~convertible~~to ~~promissory~~issue ~~note in the original principal amount of $10~~250,000 ~~to a lender. The Note was due on June 9~~,000 ~~2021,~~shares ~~is currently in default, and carries an interest rate~~ of ~~10%~~common ~~per annum~~stock. There ~~The~~were ~~Note~~no isequity ~~due~~transactions ~~and~~during ~~payable~~the insix ~~full~~months ~~unless~~ended ~~converted~~June ~~partially~~30, 2024 or in2023, ~~its~~resulting ~~entirety~~in ~~upon~~1,135,194 ~~the election of the lender into fully paid and non-assessable~~ shares of common stock ofissued ~~the~~and ~~Company~~outstanding at aJune ~~conversion rate of $2.50 per share. The Company recognized a beneficial conversion feature and recorded a debt discount in the amount of $6~~30,~~200,~~ ~~which was amortized over the life of the promissory note. At March 31,~~ 2024 and December 31, 2023,. ~~the unamortized~~

9NOTE 6 – GOING CONCERN

~~BIOETHICS~~The accompanying unaudited condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, ~~LTD~~which contemplate continuation of the Company as a going concern. However, the Company has incurred losses since its inception totaling $1,353,464 and has no on-going operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. In this regard, management is proposing to raise any necessary additional funds not provided by operations through loans, additional sales of its common stock, or through a possible business combination. There is no assurance that the Company will be successful in raising this additional capital or in achieving profitable operations. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

~~NOTES~~NOTE TO7 – ~~UNAUDITED~~LOSS ~~CONDENSED~~PER ~~FINANCIAL STATEMENTS~~SHARE

~~THREE~~The ~~MONTHS~~computation ~~ENDED~~of ~~MARCH~~basic ~~31,~~loss ~~2024~~per ~~and~~share ~~2023~~is based on the weighted average number of shares outstanding during each period.

~~debt discount was $- 0-, and the net convertible note balance was $~~10~~,000. The~~ ~~amortization~~Table of debt discount was $-0- during the three months ended March 31, 2024 and 2023, respectively. Interest expense for the three months ended March 31, 2024 and 2023 totaled $249 and $247, respectively, resulting in accrued interest at March 31, 2024 and December 31, 2023 of $3,810 and $3,562, respectively. Principal balance on the note at March 31, 2024 and December 31, 2023 was $10,000.Contents

~~On August 3~~BIOETHICS, ~~2020, the Company issued a convertible promissory note in the original principal amount of $15,000 to a lender~~LTD. The Note was due on August 3, 2021, is currently in default, and carries an interest rate of 8% per annum. The Note is due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $7.00 per share. The Company did not recognize a beneficial conversion feature or debt discount as the conversion price was higher than the market price at the time of issuance of the note. Interest expense for the three months ended March 31, 2024 and 2023 totaled $298 and $296, respectively, resulting in accrued interest at March 31, 2024 and December 31, 2023 of $4,392 and $4,093. Principal balance on the note at March 31, 2024 and December 31, 2023 was $15,000.

~~NOTE~~NOTES 5TO ~~– EQUITY~~UNAUDITED ~~TRANSACTIONS~~CONDENSED FINANCIAL STATEMENTS

~~The~~SIX ~~Company~~MONTHS isENDED ~~authorized~~JUNE ~~to issue 250~~30,~~000,000~~ ~~shares of common stock. There were no equity transactions during the three months ended March 31,~~ 2024 ~~or 2023, resulting in 1,135,194 shares of common stock issued~~ and ~~outstanding at March 31, 2024 and December 31,~~ 2023.

~~NOTE~~The 6following -data ~~GOING~~show ~~CONCERN~~the amounts used in computing loss per share for the six months ended:

The accompanying unaudited condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, the Company has incurred losses since its inception totaling $1,317,532 and has no on-going operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. In this regard, management is proposing to raise any necessary additional funds not provided by operations through loans, additional sales of its common stock, or through a possible business combination. There is no assurance that the Company will be successful in raising this additional capital or in achieving profitable operations. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

	June 30, 2024			June 30, 2023

Net loss (numerator)	$	(75,585	)	$	(50,446	)
Weighted average shares outstanding (denominator)		1,135,194			1,135,194
Basic and fully diluted net loss per share amount	$	(0.07	)	$	(0.04	)

~~NOTE~~The 7computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year plus the common stock equivalents as detailed in the following chart. For the six months ended June 30, 2024 and 2023, the inclusion of these shares on the statements of operations would have resulted in a weighted average shares fully diluted number that was anti-dilutive, ~~LOSS~~and ~~PER~~as ~~SHARE~~such they are excluded.

The ~~computation~~following ofdata ~~basic~~show ~~loss~~the ~~per~~fully ~~share~~diluted isshares ~~based~~for on the ~~weighted~~six ~~average~~months ~~number~~ended ofJune ~~shares~~30, ~~outstanding~~2024 ~~during~~and ~~each period.~~ 2023:

The following data show the amounts used in computing loss per share for the three months ended:

	June 30,
	2024		2023

Basic weighted average shares outstanding		1,135,194		1,135,194
Convertible debt		15,351		14,694
Total		1,150,545		1,149,888

		March 31, 2024		March 31, 2023
Net loss (numerator)	$	(39,653)	$	(23,636)
Weighted average shares outstanding (denominator)		1,135,194		1,135,194
Basic and fully diluted net loss per share amount	$	(0.03)	$	(0.02)

NOTE 8 – SUBSEQUENT EVENTS

~~The~~On ~~computation~~July of1, ~~diluted~~2024 ~~earnings~~the ~~per~~Company ~~common~~filed ~~share~~with isthe ~~based~~State onof ~~the~~Nevada ~~weighted~~for ~~average~~the ~~number~~designation of 6,000,000 shares ~~outstanding~~of ~~during~~Series ~~the~~A ~~year~~Preferred ~~plus~~Stock ~~the~~(“Series ~~common~~A”) ~~stock~~with ~~equivalents~~a aspar ~~detailed~~value inof ~~the~~$0.01 ~~following~~per ~~chart~~share. ~~For~~ ~~the~~Each ~~three~~share ~~months~~of ~~ended~~Series ~~March~~A ~~31,~~has ~~2024~~liquidation ~~and~~priority ~~2023~~over any Junior Securities, is convertible into common stock at the ~~inclusion~~option of ~~these~~the ~~shares~~holder on a ten-for-one basis and carries no common votes unless and until converted to common stock at which time the ~~statements~~converted ofshares ~~operations~~are entitled to vote on any matter submitted to common stockholders. The Series A shares are not entitled to dividends unless and until converted to common stock at which time they would have ~~resulted~~dividend inrights as common stock holders. On July 25, 2024 the Board of Directors voted to issue a ~~weighted~~total ~~average~~of 620,000 shares ~~fully~~of ~~diluted~~Series ~~number~~A ~~that~~Preferred ~~was anti-dilutive~~Stock, ~~and~~valued asat ~~such~~approximately ~~they~~$3.56 ~~are~~per ~~excluded~~share, to eight individuals and entities.

1011 Table of Contents

BIOETHICS, LTD.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

THREE MONTHS ENDED MARCH 31, 2024 and 2023

The following data show the fully diluted shares for the three months ended March 31, 2024 and 2023:

	March 31,
	2024	2023
Basic weighted average shares outstanding	1,135,194	1,135,194
Convertible debt	15,061	14,694
Total	1,150,255	1,149,888

NOTE 8 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and determined there are no events requiring disclosure.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion in conjunction with our financial statements, which are included elsewhere in this report. The following information contains forward-looking statements. (See “Forward-Looking Statements” below.)

FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements reflect the Company’s views with respect to future events based upon information available to it at this time. These forward-looking statements are subject to certain uncertainties and other factors that could cause actual results to differ materially from these statements. The words “anticipates,” “believes,” “estimates,” “expects,” “plans,” “projects,” “targets,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, changes in assumptions, future events or otherwise.

General

The Company is a shell company that conducts no active business operations and is seeking business opportunities for acquisition or participation by the Company.

The Report of Independent Registered Public Accounting Firm on the Company’s December 31, 2023 audited financial statements addresses an uncertainty about the Company’s ability to continue as a going concern, indicating that the Company has incurred losses since its inception and has no on-going operations. The report further indicates that these factors raise substantial doubt about the Company’s ability to continue as a going concern. At ~~March~~June 3130, 2024, the Company had a working capital deficit of $~~815~~851,~~918~~850 and an accumulated deficit since inception of $1,~~317~~353,~~532~~464. The Company incurred net losses of $3975,~~653~~585 and $2350,~~636~~446 for the ~~three~~six months ended ~~March~~June 3130, 2024 and 2023, respectively. The Company has not entered into any agreements or arrangements for the provision of additional debt or equity financing and there can be no assurance that it will be able to obtain the additional debt or equity capital required to continue its operations.

~~The~~On ~~three~~or ~~months~~about ~~ended~~June ~~March~~18, 312024, the Company and SILQ Technologies Corporation, a Delaware corporation (“SILQ”), entered into a non-binding letter of intent (the “Letter of Intent’’) to explore entering into a transaction wherein the Company acquires SILQ pursuant to a reverse triangular merger (the “Merger”), as further described in the Company’s Form 8-K filed June 26, 2024. ~~compared~~The terms of the proposed Merger and related transactions must be set forth in a definitive agreement. There are no assurances that the Company will be successful in negotiating an acceptable definitive agreement, when or whether a definitive agreement will be reached between the parties, or that the proposed Merger will be consummated. Even if a definitive agreement is executed, the terms of the proposed Merger may change materially from the terms set forth in the Letter of Intent. There will be many conditions to ~~March~~closing, 31many of which are outside of the parties’ control, ~~2023~~and we cannot predict whether these conditions will be satisfied. There are no assurances when or if closing will occur, even if the parties successfully negotiate and sign a definitive agreement.

The ~~Company~~Three ~~did~~and ~~not~~Six ~~conduct~~Months ~~any operations during the three months~~ ended ~~March~~June 3130, 2024 ~~and 2023. At March 31, 2024, the Company had cash and total current assets in the amount of $93,~~ compared to ~~$138~~June ~~at December 31~~30, 2023. At March 31, 2024, the Company had total current liabilities of $816,011, compared to $776,403 at December 31, 2023. The Company had a working capital deficit of $815,918 at March 31, 2024 compared to $776,265 at December 31, 2023.

The Company did not ~~generate~~conduct ~~revenues~~any operations during the ~~three~~six-month ~~months~~ periods ended ~~March~~June 3130, 2024 or ~~2022~~2023. ~~The~~ At June 30, 2024, the Company ~~incurred~~had ~~general~~cash and ~~administrative~~total ~~expenses~~current assets in the amount of $2710,~~221~~168, ~~during~~compared ~~the~~to ~~three~~$138 ~~months~~at ~~ended~~December ~~March~~ 31, 2023. At June 30, 2024, ~~compared~~the toCompany had total current liabilities of $12862,~~027~~018, ~~during~~compared ~~the~~to ~~three~~$776,403 ~~months~~at ~~ended~~December ~~March~~ 31, 2023. ~~Such~~ The ~~expenses~~Company ~~consist~~had ~~primarily~~a ofworking ~~legal~~capital ~~and~~deficit ~~accounting~~of ~~fees~~$851,850 asat ~~well~~June as30, ~~taxes~~2024 ~~and~~compared ~~annual fees required~~ to ~~maintain~~$776,265 ~~the~~at ~~Company’s~~December ~~corporate~~31, ~~status~~2023.

The Company did not generate revenues during the six-month periods ending June 30, 2024 or 2023. The Company incurred ~~other~~general and administrative expenses of $1222,~~432~~979 during the three months ended ~~March~~June 3130, 2024, compared to $1114,~~609~~812 during the three months ended ~~March~~June 3130, 2023. ~~Total~~ The ~~other~~Company ~~income~~incurred general and administrative expenses ~~consist~~ of ~~interest~~$50,200 ~~expense~~during ~~related~~the six months ended June 30, 2024, compared to $26,839 during the ~~notes~~six ~~payable~~months ~~due~~ended ~~from~~June 30, 2023. Such expenses consist primarily of legal and accounting fees as well as taxes and annual fees required to maintain the Company.’s corporate status.

~~The~~12 ~~Company~~Table ~~incurred a net loss~~ of ~~$39,653 during the three months ended March 31, 2024, compared to a net loss of $23,636 during the three months ended March 31, 2023.~~ Contents

The Company ~~has~~incurred ~~never~~other ~~had~~expenses ~~substantial~~of ~~ongoing~~$12,953 ~~operations.~~during Asthe athree ~~result~~months ended June 30, ~~since~~2024 ~~its~~compared ~~inception~~to on$11,998 ~~July~~during 26the three months ended June 30, ~~1990~~2023. The Company incurred other expenses of $25,385 during the ~~Company~~six ~~had~~months anended ~~accumulated~~June ~~deficit~~30, of2024 compared to $123,~~317~~607 during the six months ended June 30,~~532~~ as2023. Total other income and expenses consist of ~~March~~interest ~~31,~~expense ~~2024~~related to the notes payable due from the Company.

12The Company incurred a net loss of $35,932 during the three months ended June 30, 2024, compared to a net loss of $26,810 during the three months ended June 30, 2023. The Company incurred a net loss of $75,585 during the six months ended June 30, 2024, compared to a net loss of $50,446 during the six months ended June 30, 2023.

The Company has never had substantial ongoing operations. As a result, since its inception on July 26, 1990, the Company had an accumulated deficit of $1,353,464 as of June 30, 2024.

Liquidity and Capital Resources

Net cash used by operating activities was $538,~~895~~920 and $312,~~045~~422 during the ~~three~~six months ended ~~March~~June 3130, 2024 and 2023, respectively.

Net cash provided by investing activities was $-0- during both the ~~three~~six months ended ~~March~~June 3130, 2024 and 2023.

Net cash provided by financing activities was $548,~~850~~950 and $312,~~000~~600 during the ~~three~~six months ended ~~March~~June 3130, 2024 and 2023, respectively, and consisted of loans received from related and unrelated parties.

Since the Company does not generate any revenues from operations, it is dependent on sales of securities, loans, or contributions from its stockholders in order to pay its operating costs. In addition, in the event the Company locates a suitable candidate for potential acquisition, the Company will require additional funds to pay the costs of negotiating and completing the acquisition of such candidate. The Company has not entered into any agreement or arrangement for the provision of any additional funding and no assurances can be given that such funding will be available to the Company on terms acceptable to it or at all.

The Company cannot presently foresee the cash requirements of any business opportunity which may ultimately be acquired by the Company. However, since it is likely that any business it acquires will be involved in active business operations, the Company anticipates that an acquisition will result in increased cash requirements as well as increases in the number of employees of the Company.

Off-Balance Sheet Arrangements

The Company has not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that are material to investors.

Critical Accounting Policies

Due to the lack of current operations and limited business activities, the Company does not have any accounting policies that it believes are critical to facilitate an investor’s understanding of the Company’s financial and operating status.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not Applicable. The Company is a “smaller reporting company.”

Table of Contents

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer/Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (“the Exchange Act”) as of ~~March~~June 3130, 2024, the end of the period covered by this report, utilizing the Committee of Sponsoring Organizations of the Treadway Commission’s 2013 update to the Internal Control Integrated Framework. Based upon that evaluation, our Chief Executive Officer/Chief Financial Officer concluded that our disclosure controls and procedures as of ~~March~~June 3130, 2024 were not effective such that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer/Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure. A controls system cannot provide absolute assurance, however, that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934 as a process designed by, or under the supervision of, the company’s principal executive and principal financial officers and effected by the company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America and includes those policies and procedures that:

●· Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company; · Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and · Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements.

●Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and

●Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Because of the inherent limitations of internal control, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

We carried out an assessment, under the supervision and with the participation of our management, including our CEO and Interim CFO, of the effectiveness of the design and operation of our internal controls over financial reporting, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as of ~~September~~June 30, ~~2023~~2024. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control — Integrated Framework (2013). Based on that assessment and on those criteria, our CEO and Interim CFO concluded that our internal control over financial reporting was not effective as of ~~September~~June 30, ~~2023~~2024. The principal basis for this conclusion is (i) failure to engage sufficient resources regarding our accounting and reporting obligations during our startup and (ii) failure to fully document our internal control policies and procedures.

This quarterly report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. The management’s report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the SEC that permit us to provide only the management’s report in this quarterly report.

The Company’s management, including the Company’s CEO and Interim CFO, does not expect that the Company’s internal control over financial reporting will prevent all errors and all fraud. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree or compliance with the policies or procedures may deteriorate.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting during the quarter ended ~~March~~June 3130, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

14 Table of Contents

Part II---OTHER INFORMATION

Item 1. Legal Proceedings.

The Company is not a party to any material pending legal proceedings and, to the best of its knowledge; its properties are not the subject of any such proceedings.

Item 1A. Risk Factors.

Not Applicable. The Company is a “smaller reporting company.”

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

Not Applicable.

Item 4. Mine Safety Disclosures.

Not Applicable.

Item 5. Other Information.

None.

15 Table of Contents

Item 6. Exhibits

The following documents are included as exhibits to this report:

(a) Exhibits

Exhibit Number	SEC Reference Number	Title of Document	Location
ExhibitNumber	SEC Reference Number	Title of Document	Location
31.1	31	Section 302 Certification of Chief Executive and Chief Financial Officer	This Filing
32.1	32	Section 1350 Certification of Chief Executive and Chief Financial Officer	This Filing
101.INS**		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).	This Filing
101.SCH**		Inline XBRL Taxonomy Extension Schema	This Filing
101.CAL**		Inline XBRL Taxonomy Extension Calculation Linkbase	This Filing
101.DEF**		Inline XBRL Taxonomy Extension Definition Linkbase	This Filing
101.LAB**		Inline XBRL Taxonomy Extension Label Linkbase	This Filing
101.PRE**		Inline XBRL Taxonomy Extension Presentation Linkbase	This Filing
104**		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).	This Filing

**XBRL information is furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934, and is not subject to liability under those sections, is not part of any registration statement or prospectus to which it relates and is not incorporated or deemed to be incorporated by reference into any registration statement, prospectus or other document.

~~SIGNATURES~~16 Table of Contents

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.~~SIGNATURES

	Bioethics, Ltd.
Date: May 20, 2024	By /s/ Mark A. Scharmann
	Mark A. Scharmann
	President, Chief Executive Officer and
	Chief Financial Officer
	(Principal Executive and Financial Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Bioethics, Ltd.

Date: August 19, 2024	By: /s/ Mark A. Scharmann
	Mark A. Scharmann
	President, Chief Executive Officer and
	Chief Financial Officer
	(Principal Executive and Financial Officer)

Filing Compare · BIOETHICS LTD